PolyPid Ltd. (PYPD), an Israeli biopharmaceutical firm, said on Monday that its Chief Executive Officer or CEO Amir Weisberg, will retire from the service with effect from July 1.
Weisberg will be succeeded by the company's present Chief Financial Officer or CFO Dikla Czaczkes Akselbrad.
Weisberg will direct a transition period with Akselbrad beginning on April 1, and will retire from the helm.
Effective March, PolyPid's Chief Operating Officer or COO Shaul Mukhtar, will also be retiring from the company, following two and a half years term.
For comments and feedback: editorial@rttnews.com